{"id":"ilumya-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2094006","moleculeType":"Small molecule","molecularWeight":"702.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-23 is a key cytokine involved in the pathogenesis of psoriasis, particularly in driving Th17 cell differentiation and skin inflammation. By selectively targeting the p19 subunit of IL-23, tildrakizumab prevents IL-23 signaling while sparing IL-12, which may reduce the risk of certain immune-related adverse events. This mechanism leads to suppression of psoriatic inflammation and improvement in skin lesions.","oneSentence":"Ilumya (tildrakizumab) is a monoclonal antibody that selectively blocks the IL-23 pathway by binding to the p19 subunit of interleukin-23, reducing inflammatory signaling in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:09.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT04991116","phase":"PHASE3","title":"Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2022-06-30","conditions":"Psoriatic Arthritis","enrollment":529},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT05683015","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2022-08-22","conditions":"Psoriasis Vulgaris","enrollment":100},{"nctId":"NCT04229836","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-12-17","conditions":"Plaque Psoriasis","enrollment":178},{"nctId":"NCT04263610","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-09-04","conditions":"Plaque Psoriasis","enrollment":190},{"nctId":"NCT04347473","phase":"PHASE4","title":"ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-06","conditions":"Psoriasis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ilumya Injectable Product","genericName":"Ilumya Injectable Product","companyName":"Psoriasis Treatment Center of Central New Jersey","companyId":"psoriasis-treatment-center-of-central-new-jersey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ilumya (tildrakizumab) is a monoclonal antibody that selectively blocks the IL-23 pathway by binding to the p19 subunit of interleukin-23, reducing inflammatory signaling in psoriasis. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}